Jubilant Life Sciences Ltd. (530019.BY) has bought out U.S.-based Eli Lilly & Co.'s (LLY) stake in the equal joint venture formed by the two companies in 2008 to provide outsourced early-stage drug development services, its executive director for finance said Wednesday. "The joint venture, Vanthys Pharmaceuticals, will now be 100% owned by Jubilant Life," R. Sankaraiah told Dow Jones Newswires. Vanthys Pharmaceuticals, based in Bangalore, was working on taking experimental drugs from the stage of animal trials through to mid-stage human testing, before returning successful assets to the sponsors for further development.
